Skip to main content

Table 1 Characteristics of HCC patients

From: Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection

Variables

Median (range)/Mean±SD/N (%)

Gender(male/female)

298(82.8%)/62(17.2%)

Age,years

59.2±10.9

HBV(yes/no)

311(86.4%)/49(13.6%)

Anti-HBV(yes/no)

129(35.8%)/231(64.2%)

Family history of HCC

16(4.4%)/344(95.6%)

Hypertension(yes/no)

101(28.1%)/259(71.9%)

Diabetes(yes/no)

47(13.1%)/313(86.9%)

ALT, U/L (≤50/>50)

287(79.7%)/73(20.3%)

ALP, U/L (≤125/>125)

286(79.4%)/74(20.6%)

GGT, U/L (≤60/>60)

204(56.7%)/156(43.3%)

PT, seconds (≤13/>13)

303(84.2%)/57(15.8%)

ALBI(≤-2.60/ -2.60 to -1.39/>-1.39)

236(65.6%)/120(33.3%)/4(1.1%)

DB, umol/l (≤8/>8)

297(82.5%)/63(17.5%)

INR(≤1/>1)

85(23.6%)/275(76.4%)

AFP,ng/mL (≤20/20 to 400/>400)

167(46.4%)/96(26.7%)/97(26.9%)

PNI

48.9(26.5,73.3)

APRI

0.22(0.04,4.58)

ALRI

21.70(5.67,514.62)

ANRI

10.72(1.51,209.06)

SII

296.59(50.80,7846.67)

NLR

2.00(0.40,73.33)

PLR

102.18(30.91,500.00)

MLR

0.29(0.12,5.17)

SIRI

0.85(0.21,75.43)

Pathological differentiation(well/moderate/poor)

167(46.4%)/96(26.7%)/97(26.9%)

MVI(yes/no)

180(50%)/180(50%)

Cirrhosis(yes/no)

173(48.1%)/187(51.9%)

Number of tumours(solitary/multiple)

290(80.6%)/70(19.4%)

Tumour diameter, cm

4.98±3.07

Tumour capsule(yes/no)

299(83.1%)/61(16.9%)

PVTT(yes/no)

30(8.3%)/330(91.7%)

Child-Pugh grade (A/B)

354(98.3%)/6(1.7%)

AJCC T stage (I - II /III - IV)

280(77.8%)/80(22.2%)

  1. Abbreviations: HBV Hepatitis B Virus, ALT alanine aminotransferase, ALPalkaline phosphatase, GGT γ-glutamyl transpeptidase, PT prothrombin time, DB direct bilirubin, INR international normalized ratio, AFP alpha-fetoprotein, MVI microvascular invasion, PVTT portal vein tumour thrombosis